Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Transplant. Dec 24, 2013; 3(4): 99-112
Published online Dec 24, 2013. doi: 10.5500/wjt.v3.i4.99
Published online Dec 24, 2013. doi: 10.5500/wjt.v3.i4.99
Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies
Daniel KL Cheuk, Department of Paediatrics and Adolescent Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, China
Author contributions: Cheuk DKL solely contributed to this paper.
Supported by The University of Hong Kong
Correspondence to: Daniel KL Cheuk, FHKAM, Department of Paediatrics and Adolescent Medicine, the University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, China. cheukkld@hkucc.hku.hk
Telephone: +86-852-22553909 Fax: +86-852-22551523
Received: August 28, 2013
Revised: November 15, 2013
Accepted: December 9, 2013
Published online: December 24, 2013
Processing time: 124 Days and 17.9 Hours
Revised: November 15, 2013
Accepted: December 9, 2013
Published online: December 24, 2013
Processing time: 124 Days and 17.9 Hours
Core Tip
Core tip: Randomized controlled trials (RCTs) suggest no difference in survival between peripheral blood stem cell (PBSC) and bone marrow (BM) in matched sibling transplant for patients with hematological malignancies. PBSC may result in fewer relapse in high risk patients but more severe graft-versus-host disease (GVHD). For unrelated donor, the only RCT suggests PBSC and BM result in comparable survivals, with PBSC resulting in fewer graft failure but more chronic GVHD. RCT is not available to compare cord blood with BM or PBSC. The risks and benefits of different sources of stem cells likely change with transplant methods and manipulation of grafts.